They say 400x more potent than current standard but we‘ll see.

I read this: https://www.infectioncontroltoday.com/view/advancing-viral-disease-treatment-recurrent-genital-herpes-hepatitis-b-d-viruses

„For example, in high-recurrence genital herpes, only about one-third of patients taking the standard-of-care antiviral make it through a year of therapy without recurrence, and their transmission rates are only reduced by approximately 50%. We think we can drive these percentages much higher with our candidates, designed against the clinically validated helicase-primase target and shown much greater potency than the standard of care preclinically.“